GSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regression

GSK pledges £44.5M in near-term for UK biotech to explore cause of liver fibrosis regression is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

James Waldron · 2026-06-08

GSK’s latest hepatology partnership is posing a less-asked question—how do you stop patients’ liver fibrosis from regressing?

Source: FierceBiotech